James Fox, MD
Ophthalmology · Grand Junction, CONPI 1295997351
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.5%), other and food and beverage — rather than concentrated in one kind of arrangement. Glaukos Corporation accounts for 88.0% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $16,891, more than ten times the $455 reported in 2019. Among ophthalmology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 136 payments — averaging $206.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$25K
- Alcon$1K
- AbbVie$382
- NEW World Medical,inc.$357
- Rxsight Inc$251
- Rayner Intraocular Lenses Limited$221
- plus $1K from 14 others
Across 236 payments — averaging $3790.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$665K
- Bausch Health US, LLC$144K
- Alcon Research LLC$65K
- AbbVie$20K
What the payments were for
- Consulting fees$13,05047%
- Speaking & faculty fees$390%
- Travel & lodging$2,5769%
- Food & beverage$4,83817%
- Education$300%
- Gifts$450%
- Other$7,47527%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 30 | $24,677 |
| Alcon | 34 | $1,032 |
| AbbVie(2 entities) | 7 | $382 |
| NEW World Medical,inc. | 3 | $357 |
| Rxsight Inc | 5 | $251 |
| Rayner Intraocular Lenses Limited | 5 | $221 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $211 |
| Kala Pharmaceuticals, Inc. | 8 | $162 |
| Sun Pharmaceutical Industries Inc. | 8 | $139 |
| Novartis | 7 | $135 |
| Sight Sciences, Inc. | 6 | $117 |
| Boston Scientific | 3 | $66 |
| Biotissue Holdings Inc. | 4 | $58 |
| Tarsus Pharmaceuticals, Inc. | 3 | $56 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Harrow Eye, LLC | 3 | $48 |
| Beaver-visitec International, Inc. | 1 | $36 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$15,633
- iDoseTR$663
- iStent$306
- iStent inject W$306
- DURYSTA$250
- iStent Inject Trabecular Micro-Bypass System$171
- Kahook Dual Blade$164
- Clearpath$164
- Ahmed Glaucoma Valve$164
- Streamline$164
- ARGOS$141
- Clareon$136
- OMIDRIA$128
- RayOne EMV$128
- RayOne Spheric$128
- RayOne Aspheric$128
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT CONTACT LENS$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
How this compares
$28,053 in reported general payments places this provider in the 90th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 54 | $66,821 |
| XiidraLifitegrast | 53 | $50,687 |
| RhopressaNetarsudil Mesylate | 39 | $23,418 |
| LumiganBimatoprost | 39 | $20,490 |
| Prednisolone Acetate | 486 | $15,704 |
| MoxifloxacinMoxifloxacin Hcl | 404 | $9,964 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $8,452 |
| Cyclosporine | 13 | $8,432 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $8,145 |
| Ketorolac Tromethamine | 401 | $7,000 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $6,737 |
| Latanoprost | 371 | $4,546 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 217 | $3,752 |
| Brimonidine Tartrate | 123 | $2,481 |
| Pilocarpine Hcl | 33 | $2,029 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $382 | $95,456116 claims |
| Bausch & Lomb Americas Inc.Xiidra | $18 | $50,68753 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $22 | $31,87055 claims |
| AlconSimbrinza | $1,032 | $6,73716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Grand Junction
- Mark PackerBoulder$3.5M
- Jon DishlerGreenwood Village$1M
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Geeta Lalchandani LalwaniBoulder$319K
- Richard DavidsonAurora$316K
- Steven DeweyColorado Springs$246K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.